Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

84 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Dual mTOR1/2 Inhibitor Sapanisertib (FTH-003/TAK-228) in Combination With Weekly Paclitaxel in Patients With Previously Treated Metastatic Urothelial Carcinoma: A Phase II Open-Label Study.
Bellmunt J, Maroto P, Bonfill T, Vazquez F, Perez-Gracia JL, Juanpere N, Hernandez-Prat A, Hernandez-Llodra S, Rovira A, Juan O, Rodriguez-Vida A. Bellmunt J, et al. Among authors: juan o. Clin Genitourin Cancer. 2024 Oct;22(5):102123. doi: 10.1016/j.clgc.2024.102123. Epub 2024 May 23. Clin Genitourin Cancer. 2024. PMID: 38905731 Clinical Trial.
[Hepatotoxicity due to flutamide].
Ruiz R, Casañ R, Juan O. Ruiz R, et al. Among authors: juan o. Aten Primaria. 2001 Nov 15;28(8):565. doi: 10.1016/s0212-6567(01)70449-0. Aten Primaria. 2001. PMID: 11792276 Free PMC article. Spanish. No abstract available.
Safety and efficacy of avelumab plus carboplatin in patients with metastatic castration-resistant prostate cancer in an open-label Phase Ib study.
Rodriguez-Vida A, Maroto P, Font A, Martin C, Mellado B, Corbera A, Orrillo M, Reig O, Querol R, Rios-Hoyo A, Cano L, Alonso J, Martinez G, Galtes S, Taus A, Martinez-Garcia M, Juanpere N, Juan O, Bellmunt J. Rodriguez-Vida A, et al. Among authors: juan o. Br J Cancer. 2023 Jan;128(1):21-29. doi: 10.1038/s41416-022-01991-4. Epub 2022 Oct 26. Br J Cancer. 2023. PMID: 36289372 Free PMC article. Clinical Trial.
Induction avelumab followed by chemoimmunotherapy and maintenance versus chemotherapy alone as first-line therapy in cis-ineligible metastatic urothelial carcinoma (INDUCOMAIN): a randomized phase II study.
Rodriguez-Vida A, Valderrama BP, Castellano D, Pinto A, Mellado B, Puente J, Climent MA, Domenech M, Vazquez F, Perez-Gracia JL, Bonfill T, Morales-Barrera R, Gonzalez-Billalabeitia E, Garcia-Del-Muro X, Maroto P, Navarro-Gorro N, Juanpere N, Juan O, Bellmunt J. Rodriguez-Vida A, et al. Among authors: juan o. ESMO Open. 2024 Sep;9(9):103690. doi: 10.1016/j.esmoop.2024.103690. Epub 2024 Aug 29. ESMO Open. 2024. PMID: 39214051 Free PMC article. Clinical Trial.
Osimertinib in advanced EGFR-T790M mutation-positive non-small cell lung cancer patients treated within the Special Use Medication Program in Spain: OSIREX-Spanish Lung Cancer Group.
Provencio M, Terrasa J, Garrido P, Campelo RG, Aparisi F, Diz P, Aguiar D, García-Giron C, Hidalgo J, Aguado C, González JG, Esteban E, Gómez-Aldavarí L, Moran T, Juan O, Chara LE, Marti JL, Castro RL, Ortega AL, Moreno EM, Coves J, Sánchez Peña AM, Bosch-Barrera J, Gastaldo AS, Núñez NF, Del Barco E, Cobo M, Isla D, Majem M, Navarro F, Calvo V. Provencio M, et al. Among authors: juan o. BMC Cancer. 2021 Mar 6;21(1):230. doi: 10.1186/s12885-021-07922-5. BMC Cancer. 2021. PMID: 33676426 Free PMC article.
LungBEAM: A prospective multicenter study to monitor stage IV NSCLC patients with EGFR mutations using BEAMing technology.
Garrido P, Paz-Ares L, Majem M, Morán T, Trigo JM, Bosch-Barrera J, Garcίa-Campelo R, González-Larriba JL, Sánchez-Torres JM, Isla D, Viñolas N, Camps C, Insa A, Juan Ó, Massuti B, Paredes A, Artal Á, López-Brea M, Palacios J, Felip E. Garrido P, et al. Among authors: juan o. Cancer Med. 2021 Sep;10(17):5878-5888. doi: 10.1002/cam4.4135. Epub 2021 Jul 23. Cancer Med. 2021. PMID: 34296539 Free PMC article. Clinical Trial.
PECATI: A Multicentric, Open-Label, Single-Arm Phase II Study to Evaluate the Efficacy and Safety of Pembrolizumab and Lenvatinib in Pretreated B3-Thymoma and Thymic Carcinoma Patients.
Remon J, Girard N, Novello S, de Castro J, Bigay-Game L, Bernabé R, Greillier L, Mosquera J, Cousin S, Juan O, Sampayo M, Besse B. Remon J, et al. Among authors: juan o. Clin Lung Cancer. 2022 May;23(3):e243-e246. doi: 10.1016/j.cllc.2021.07.008. Epub 2021 Jul 20. Clin Lung Cancer. 2022. PMID: 34393061 Clinical Trial.
84 results